WO2001030420A1 - Method and apparatus for placement and activation of a medical device within a body cavity - Google Patents

Method and apparatus for placement and activation of a medical device within a body cavity Download PDF

Info

Publication number
WO2001030420A1
WO2001030420A1 PCT/US2000/029701 US0029701W WO0130420A1 WO 2001030420 A1 WO2001030420 A1 WO 2001030420A1 US 0029701 W US0029701 W US 0029701W WO 0130420 A1 WO0130420 A1 WO 0130420A1
Authority
WO
WIPO (PCT)
Prior art keywords
tube
infuser
inner tube
delivery device
ejector
Prior art date
Application number
PCT/US2000/029701
Other languages
French (fr)
Inventor
John Patrick Greelis
Mikxay Sirivong
David G. Matsuura
W. Tate Scott
Paul F. Zupkas
Original Assignee
Situs Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Situs Corporation filed Critical Situs Corporation
Priority to AU17532/01A priority Critical patent/AU1753201A/en
Publication of WO2001030420A1 publication Critical patent/WO2001030420A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/95Instruments specially adapted for placement or removal of stents or stent-grafts

Definitions

  • the present invention relates to a method and apparatus for delivering a medical device into a body cavity.
  • Retrograde introduction of a drug by a urethral catheter is suitable only for limited situations and has inherent drawbacks.
  • U.S. Patent No. 5,301 ,688 discloses a method for treating bladder cancers through electromotive administration of drugs into the bladder via a catheter. This type of treatment is suitable primarily for care administered on an in-patient or out-patient basis, not for chronic treatment.
  • U.S. Patent No. 5,219,334 discloses an infuser for connection to a catheter that is suitable for long-term delivery of drug into a patient through the catheter. This device requires continuous cathetenzation in order to function adequately.
  • Pryor et al. U.S. Patent No. 5,062,829, discloses a helical device for insertion into a body cavity, e.g., the rumen of a bovine.
  • the helical device includes a drug that can be released over time and further includes a biodegradable portion so that, upon exhaustion of the drug, the device can break up and be naturally eliminated.
  • Garay et al. U.S. Patent No. 4,925,446, discloses an infusion device having an annular shape that is suitable for delivering materials into the stomach over a prolonged period of time. None of these prior art devices address the problem of intravesical drug delivery where drug delivery is intended to continue over a prolonged period of time while the patient maintains an active lifestyle.
  • urge incontinence Two of the major causes of urge incontinence are detrusor instability and hyperreflexia.
  • Oxybutynin is a pharmacological agent that has been used to treat urge incontinence with some success.
  • This drug is an anticholinergic agent that blocks contraction of the bladder and has direct smooth muscle relaxant properties.
  • this drug is associated with significant side effects upon oral administration, including dry skin, dry mouth, blurred vision, constipation, and urinary retention.
  • oxybutynin may lead to tachycardia. Because of the side effects, the accepted oral dose of oxybutynin is limited to 10 15 mg per day
  • Interstitial cystitis is a debilitating condition in which the lining of the bladder is irritated, creating a sense of urgency and pain. The condition results in extreme frequency of urination, sometimes as many as 40, 50, or more times per day and can lead to cystectom ⁇ .
  • Sufferers of interstitial cystitis can be treated by administration of certain drugs, including pentosanpolysulfate, manufactured by Bene of Kunststoff, Germany and distributed by ALZA Corporation of Palo Alto, CA under the trademark ELMIRON.
  • pentosanpolysulfate manufactured by Bene of Kunststoff, Germany and distributed by ALZA Corporation of Palo Alto, CA under the trademark ELMIRON.
  • a delivery device suitable for delivering an infuser into a body cavity.
  • the delivery device has a handle.
  • An ejector tube extends through the handle.
  • a hollow inner tube is disposed within the ejector tube in a sliding relationship therewith.
  • the hollow inner tube is adapted to provide a passageway for a substance from the handle to a distal end of the hollow inner tube.
  • the distal end of the hollow inner tube is adapted to couple to an infuser device
  • the ejector tube is configured to slide distally relative to the inner tube and press against the infuser device causing ejection of the infuser device from the distal end of the hollow inner tube.
  • the device has a locking mechanism configured to prevent the ejector tube from sliding with respect to the inner tube.
  • the ejector tube is configured to be passed through the urethra of a mammalian.
  • a device such as an infuser is delivered into the organ of a patient, such as a bladder.
  • An introducer and obturator are inserted through the urethra of the patient.
  • the obturator is withdrawn.
  • a delivery device is inserted through the introducer.
  • the delivery device has a handle, an ejector tube and a hollow inner tube shdably disposed within the ejector tube.
  • the distal end of the inner tube is coupled to the infuser.
  • a substance is passed through the hollow inner tube from the handle to a distal end of the hollow inner tube and into the infuser device.
  • the ejector tube slides with respect to the inner tube causing the distal end of the ejector tube to press against the infuser device, thereby ejecting the infuser device into the bladder.
  • a locking mechanism is deactivated before the step of sliding.
  • FIG. 1 is a perspective view of a delivery device
  • FIG. 2 is a cross section of the delivery device of FIG. 1 taken along line A-A
  • FIG. 2A is an expanded view of the distal end of the tube portion.
  • FIG. 3 is a perspective view of an alternate embodiment of a delivery device with an infuser attached;
  • FIG. 4 is a cross-section of a portion of the delivery device of FIG. 3 taken along line B-B;
  • FIG. 5 is a perspective view of an obdurator;
  • FIG. 6 is a perspective view of an introducer; and
  • FIG. 6A is a perspective view of the obdurator installed within the introducer.
  • FIG. 7A 7F represent steps in utilizing the introducer and delivery device to place an infuser into a bladder.
  • FIG. 8A 8C are front and perspective views of a locking mechanism.
  • the present invention includes a unique delivery device and method suitable for delivering an infuser device into a body cavity such as the bladder.
  • the invention can be used to introduce an infuser such as described in co- pending U.S. Patent application Serial No. 09/041,475, filed March 11 , 1998, titled “Intravesical Infuser", and also described in co pending U S. Provisional application Serial No. 60/130,750, filed April 23, 1999, titled "Pressure Responsive Valve For Use With An Intravesical Infuser", each of which is assigned to the assignee of the present invention and incorporated in its entirety herein.
  • the delivery device can also be utilized to deliver an infuser into a body cavity, such as delivering an infuser into a bladder via the urethra, and then fill the infuser with a substance such as a drug. The delivery device can then be removed leaving the infuser in place in the body cavity.
  • the delivery device 10 has a handle portion 12 and tube portion 14
  • the tube portion can be rigid, flexible, semi flexible or a combination thereof.
  • the rigidity and flexibility of the tube portion 14 can be varied according to, for example, whether the route to be traversed by the tube is straight or curved.
  • the length of the tube portion 14 can be varied according to the length of the route to be traversed by the delivery device. For example, the when the delivery device is used to deliver a device such as an infuser into a human bladder, the length of the tube portion 14 should exceed the length of the typical human urethra. Similarly, the overall diameter of the tube portion should correspond to the delivery route.
  • the diameter of the tube portion 14 should be such that it can safely be inserted into a human urethra when the urethra is to be the delivery routed into the bladder.
  • the outer layer of the tube portion 14 visible in FIG. 1 is the ejector tube 24.
  • a connector in the form of a distal luer fitting 16 is located at the distal end of the tube portion 14.
  • An 0-r ⁇ ng 18 is located at the beginning of a tapered portion 20 of the handle 12
  • a hollow generally cylindrical guide 22 for receiving a syringe barrel therein is located at the end of the handle 12 opposite the tube portion 14.
  • FIG. 2 is a cross-section of the delivery device of FIG. 1 taken along line A A.
  • FIG. 2A is an expanded view of the distal portion B of the tube portion 14.
  • the tube portion 14 includes an outer layer in the form of an ejector tube 24 which extends through the handle portion 12.
  • the ejector tube passes through a front opening 34 in the handle 12 and extends through the handle 12, exiting through a rear opening 36 adjacent to the cylindrical guide 22.
  • a trigger 26 is attached to the end of the ejector tube 24.
  • a hollow, inner tube 28 is located within the ejector tube 24.
  • the inner tube 28 and the ejector tube 24 are moveable with respect to each other.
  • the distal end of the inner tube 28 is coupled to and in fluid communication with the distal luer fitting 16.
  • the distal luer fitting 16 can provide a releasable connection for a device, such as an infuser, that is to be delivered by the delivery device.
  • the inner tube 28 extends through an opening 38 in the wall of the ejector tube 24 within the handle 12.
  • the proximal end of the inner tube 28 is coupled to and in fluid communication with a connector in the form of a second luer fitting 30.
  • the second luer fitting 30 extends from the base 23 of the cylindrical guide 22 away from the inner tube 28.
  • the second luer fitting 30 provides a connection for a device such as a syringe.
  • the second luer fitting 30 can be formed as an integral part of the handle 12 or it can be formed as a separate part and attached to the handle 12 with an appropriate fastening mechanism such as epoxy or a mechanical fastener
  • the luer fitting 30 forms an attachment point for the proximal end of the inner tube 28 and maintains the inner tube 28 in a fixed position with respect to the handle 12.
  • the second luer fitting 30, inner tube 28 and distal luer fitting 16 form a delivery conduit. Fluid which is introduced through the luer fitting 30 can travel through inner tube 28 and exit through distal luer fitting 16.
  • Luer fitting 30, inner tube 28 and luer fitting 16 form a lumen or pathway.
  • more than one such lumen can be provided in the delivery device so that, for example, different substances can be separately transmitted through the delivery device.
  • one or more optic fibers can be placed in the lumens to allow imaging.
  • An adapter sleeve 32 is located in the distal end of the ejector tube 24 The adapter sleeve is fixed, such as with epoxy, to the ejector tube 24 and encircles the distal portion of the inner tube 28. The adapter sleeve 32 forms the distal end of the ejector tube 24
  • the ejector tube 24 is shdably retained within the front opening 34 and rear opening 36 of the handle 12
  • the ejector tube 24 can move shdably within those openings.
  • the distance which the ejector tube 24 can slide is limited by the length of the opening 38 through which inner tube 28 passes.
  • the edge of opening 38 coming into contact with inner tube 28 limits the travel of ejector tube 24.
  • the handle 12 includes the tapered portion 20 which extends from front opening 34 to a groove 42 which receives the 0 ring 18 (not shown in FIG. 2).
  • An outer wall 44 of the handle 12 extends from the groove 42 to the end of the cylindrical guide 22.
  • the handle 12 is formed in sections which are coupled together using male and female fittings 48 and an adhesive. If the delivery device is to be used to deliver a device that is not to be filed with a drug or other substance after it has been delivered into an organ or other location within a body, the delivery device can be simplified in that there would be no need for receiving a syringe barrel and being able to transmit the substance through the delivery device. All that would be required is the ability to retain the device until it is delivered or inserted and the ability to then release the device.
  • the inner tube 28 provides an end adapted to releasably connect to an infuser, such as the distal luer fitting 16 or alternative connection mechanisms such as a simple pressure fit or connection mechanisms known to those of skill in the art may be employed.
  • the opposite end of the inner tube is then configured to receive a drug or other substance to be transmitted to the infuser via the conduit or lumen inside of the inner tube 28.
  • the opposite end may have a luer fitting configured to connect to a syringe.
  • the delivery device 100 includes a handle portion 110 and a tube portion 1 12.
  • the tube portion 1 12 can be rigid, flexible, semi-rigid or a combination thereof.
  • the handle portion 110 includes a front handle 1 14 and a rear handle 1 16.
  • a proximal luer connector 118 extends from the rear of the rear handle 1 16.
  • a distal luer fitting 120 is located at the distal end of the tube portion 112.
  • An infuser device 122 is shown coupled to the distal luer fitting 120.
  • a hollow inner tube 124 extends through a central, tubular passageway in the front handle 114.
  • the inner tube 124 also extends through rear handle 116 and terminates at the luer connector 1 18.
  • the inner tube 124 is fastened to the rear handle 116.
  • the fastening can be accomplished through a friction fit or through the use of a fastener such as epoxy.
  • the inner tube 124 can slide freely within the passageway in the front handle 114 through which it passes.
  • the inner tube 124 also extends within the length of the ejector tube 126.
  • the distal end of the inner tube 124 is connected to and in fluid communication with the distal luer fitting 120 (see FIG. 3).
  • the inner tube 124 also slides freely within the ejector tube 126.
  • the luer connector 1 18, inner tube 124 and distal luer fitting 120 form a delivery conduit.
  • the ejector tube 126 extends partway into the front handle 114 and is firmly coupled to the front handle
  • the distal end of the ejector tube 126 may also include an adapter sleeve in the same manner as was described with respect to the delivery device shown in FIG. 2.
  • Movement of the rear handle 1 16 in the direction of arrow C and the front handle 1 14 in the direction of arrow D causes the inner tube to move in a direction opposite the movement of the ejector tube.
  • This movement causes the distal luer fitting 120 to be withdrawn into the ejector tube.
  • the withdrawal of the inner tube into the ejector tube causes the distal end of the ejector tube 129 (see FIG. 3) to come into contact with an end surface 131 of the infuser 122 thereby separating the infuser 122 from the distal luer fitting 120.
  • the obdurator 200 includes a rigid cylindrical shaft 210 having a dilator 212 at its distal end.
  • the dilator 212 includes a cylindrical, tapered shaft 218 which extends distally from an opening 216 in the shaft 210 and terminates at a hemispherical tip 220.
  • a base 214 is located at the proximal end of the obdurator 200, opposite to the dilator 212.
  • FIG. 5A is a cross sectional view of the dilator 212.
  • the tapered shaft 218 is formed from soft, 20 50 shore A si cone and has a protrusion 213 which is configured to extend over the opening 216
  • a rigid portion 215 provide sufficient rigidity to the dilator 212 in order to be effective.
  • the introducer 300 includes a hollow cylindrical tube 310 which extends from a hollow base 312.
  • the hollow base 312 is configured to receive the base 214 of the obdurator 200 of FIG. 5 and the hollow tube 310 is configured to receive the shaft 210 of the obdurator.
  • the markings 314 are placed at regular intervals along the exterior of the tube 310. The markings can be placed at intervals such as every 1 centimeter.
  • the length of the tube 310 is such that when the obdurator 200 is fully inserted into the introducer 300, the dilator 212 of the obdurator 200 extends beyond the distal opening 316 of the introducer. Referring to FIG.
  • the obdurator 200 is shown as installed within the introducer 300.
  • the tapered shaft 218 is large enough to extend over the opening 316 to provide a smooth transition for the comfort of the patient, and is pliable enough to compress and be retracted through the introducer 300.
  • FIG. 7A F a method for delivering a device such as an infuser into a body cavity utilizing the delivery device, obdurator and introducer will be described.
  • the introducer 300 is shown with the obdurator 200 fully inserted into the introducer
  • the dilator 212 is preferably formed of a material and in a shape that minimizes possible trauma to the urethra as the dilator is moved along the urethra to the bladder (see FIG. 5A)
  • the markings 314 (see FIG. 6) on the introducer can be used to assist in determining when the distal end 316 of the introducer has entered the bladder.
  • the obdurator is removed from the introducer leaving the introducer in place as depicted in FIG. 7B.
  • the delivery device 10 can serve as the obdurator thereby eliminating the need for a separate obdurator.
  • the device being delivered it is advantageous to have the device being delivered be configured in a manner similar to the dilator 212.
  • the delivery device 10 is shown having an infuser 122 coupled to the distal luer fitting 16.
  • any other device to be delivered would be in the position of the infuser 122.
  • the barrel 412 of a syringe 400 is shown inserted into the cylindrical guide 22.
  • a luer connector (not shown) at the end of the barrel 412 of the syringe 400 opposite to the plunger 414 has been connected to the second luer fitting 30 located within the cylindrical guide 22. Depressing the plunger 414 will cause fluid within the syringe barrel 412 to flow into the second luer fitting 30 through the inner tube 28 and out through the distal luer fitting 16 and into the infuser 122.
  • the infuser prior to transferring the liquid within the syringe into the infuser, the infuser must be inserted into the bladder of the patient Referring to FIG. 7D, the tube portion 14 of the delivery device 10 is shown fully inserted into the introducer 300.
  • the end of the distal luer connector reaches approximately the distal end of the introducer when the tube portion of the delivery device is fully inserted into the introducer.
  • the infuser extends approximately completely beyond the distal end of the introducer within the bladder.
  • Both the tube portion 14 and the infuser 122 have diameters such that they fit easily within and easily slide through tube 310.
  • the tapered portion 20 of the delivery device 10 also fits within the hollow base 312 of the introducer when the delivery device is fully inserted into the introducer.
  • the plunger 414 of the syringe is depressed, forcing the fluid contained within the syringe through the delivery device and into the infuser 122.
  • the trigger 26 is moved forward (towards the infuser) which causes the distal end 37 of the ejector tube 24 to come into contact with the infuser 122 and force or eject the infuser from the distal luer fitting 120.
  • the trigger 26 is pushed forward a distance sufficient to cause the distal end of the ejector tube to travel to approximately the end of the distal luer fitting 120, thereby releasing or disconnecting the infuser from the delivery device.
  • the infuser can release itself from the delivery device when it has been filled with the drug. Referring to FIG. 7F, the infuser is shown disconnected from the delivery device and is free floating within the bladder. The delivery device and the introducer are then withdrawn through the urethra.
  • the delivery device and infuser can be inserted directly without the use of the introducer or obdurator.
  • a lock mechanism is used to prevent the unintentional ejection of the infuser from the distal end of the luer fitting 120.
  • one such locking mechanism 440 is shown in front view, in perspective view and installed on a delivery device, respectively.
  • the locking mechanism 440 can be placed within the gap between the trigger 26 and the guide 22 such that the proximal end of the ejector tube 24 is between the extending members 442 as shown in FIG. 8C.
  • the height, h, of the locking mechanism 440 prevents the movement of the ejector tube 24 toward the guide 22 and, thus, prevents the ejection of the infuser.
  • the locking mechanism 440 can be in place until the infuser has been filled with drug. It can then be removed to allow the ejection of the infuser.
  • the delivery device can also be utilized to deliver other suitable objects into body cavities and to introduce liquid or semi- liquid materials into body cavities.

Landscapes

  • Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

A delivery device and method for delivering a medical device, such as an infuser, into a body cavity are disclosed. The delivery device includes an ejector tube which slidably extends through a handle. The ejector tube is configured for easy insertion through the urethra into the bladder. A hollow inner tube is located within the ejector tube and includes luer fittings at its distal and proximal ends. The luer fitting at the proximal end of the inner tube is coupled to the handle. Movement of the ejector tube relative to the inner tube causes the distal luer fitting to be withdrawn within the ejector tube and can be used to force an infuser attached to the distal luer fitting from the distal luer fitting. Materials can be transported to the infuser from the proximal luer fitting through the inner tube and out through the distal luer connector.

Description

METHOD AND APPARATUS FOR PLACEMENT AND ACTIVATION OF A MEDICAL DEVICE WITHIN A BODY CAVITY
Background of the Invention Field of the Invention
The present invention relates to a method and apparatus for delivering a medical device into a body cavity. Description of the Related Art
Delivery of drugs to organs such as the bladder are typically accomplished systemically. Systemic drug delivery through oral, intravenous, intramuscular or traπsdermal administration methods carries with it the obvious drawbacks of any systemic treatment, such as side effects. The drug may also be metabolized or altered by physiological processes and the ultimate quantity of active drug that reaches the organ may be reduced. In addition, because many drugs are not well tolerated systemically, the dosage must be limited, thereby reducing the total effective dose that reaches the organ.
Delivery of drugs to organs such as the bladder can also be accomplished by retrograde infection of the drug into the bladder, by a catheter. Retrograde introduction of a drug by a urethral catheter, however, is suitable only for limited situations and has inherent drawbacks.
See for example. Bladder Tissue Pharmacokinetics of Intravesical Taxol, Song, D, Wieπtjes, G, Au, JL, Cancer Chemotherapy and Pharmacology"" 1997, 40(4): 285-92; The Pharmacokinetics of Intravesical and Oral Oxybutynin Chloride, Massad, CA, Kogan, BA, Tngo-Rocha, FE, Journal of Urology, 1992, Aug., 148(2 Pt 2): 595-7; Advances in Drug Delivery and Targeting, Goldsteirf, D, Lewis, C, Current Opinion in Oncology, 1991 Dec. 3(6): 1096- 104; and Intravesical Hyaluronic Acid in the Treatment o\ Refractory Interstitial Cystitis, Morales, A, Emerson, L, Nickel, JC, Urology 49 (Suppl 5A): 111-113, 1997. Retrograde introduction of drug via urethral catheter is primarily used only in a hospital or managed care situation. It is not suitable for treatment of chronic urinary-tract conditions.
Stephen et al., U.S. Patent No. 5,301 ,688, discloses a method for treating bladder cancers through electromotive administration of drugs into the bladder via a catheter. This type of treatment is suitable primarily for care administered on an in-patient or out-patient basis, not for chronic treatment.
Tsukada, U.S. Patent No. 5,219,334 discloses an infuser for connection to a catheter that is suitable for long-term delivery of drug into a patient through the catheter. This device requires continuous cathetenzation in order to function adequately. Pryor et al., U.S. Patent No. 5,062,829, discloses a helical device for insertion into a body cavity, e.g., the rumen of a bovine. The helical device includes a drug that can be released over time and further includes a biodegradable portion so that, upon exhaustion of the drug, the device can break up and be naturally eliminated.
Garay et al., U.S. Patent No. 4,925,446, discloses an infusion device having an annular shape that is suitable for delivering materials into the stomach over a prolonged period of time. None of these prior art devices address the problem of intravesical drug delivery where drug delivery is intended to continue over a prolonged period of time while the patient maintains an active lifestyle. One condition, the treatment of which would benefit from the ability to deliver a drug directly to an organ over a prolonged period of time, is the treatment of urge incontinence. Two of the major causes of urge incontinence are detrusor instability and hyperreflexia. Oxybutynin is a pharmacological agent that has been used to treat urge incontinence with some success. This drug is an anticholinergic agent that blocks contraction of the bladder and has direct smooth muscle relaxant properties. Unfortunately, this drug is associated with significant side effects upon oral administration, including dry skin, dry mouth, blurred vision, constipation, and urinary retention. In patients with cardiovascular disease, oxybutynin may lead to tachycardia. Because of the side effects, the accepted oral dose of oxybutynin is limited to 10 15 mg per day
Interstitial cystitis is a debilitating condition in which the lining of the bladder is irritated, creating a sense of urgency and pain. The condition results in extreme frequency of urination, sometimes as many as 40, 50, or more times per day and can lead to cystectomγ. Sufferers of interstitial cystitis can be treated by administration of certain drugs, including pentosanpolysulfate, manufactured by Bene of Munich, Germany and distributed by ALZA Corporation of Palo Alto, CA under the trademark ELMIRON. However, there is currently no satisfactory method for delivery of pentosanpolysulfate to a patient over a prolonged period of time while permitting the patient to enjoy a relatively normal lifestyle.
Summary of the Invention In one aspect of the invention, there is provides a delivery device suitable for delivering an infuser into a body cavity. The delivery device has a handle. An ejector tube extends through the handle. A hollow inner tube is disposed within the ejector tube in a sliding relationship therewith. The hollow inner tube is adapted to provide a passageway for a substance from the handle to a distal end of the hollow inner tube. The distal end of the hollow inner tube is adapted to couple to an infuser device The ejector tube is configured to slide distally relative to the inner tube and press against the infuser device causing ejection of the infuser device from the distal end of the hollow inner tube. In one embodiment, the device has a locking mechanism configured to prevent the ejector tube from sliding with respect to the inner tube. In another embodiment, the ejector tube is configured to be passed through the urethra of a mammalian.
In another aspect of the invention, a device, such as an infuser is delivered into the organ of a patient, such as a bladder. An introducer and obturator are inserted through the urethra of the patient. The obturator is withdrawn. A delivery device is inserted through the introducer. The delivery device has a handle, an ejector tube and a hollow inner tube shdably disposed within the ejector tube. The distal end of the inner tube is coupled to the infuser. A substance is passed through the hollow inner tube from the handle to a distal end of the hollow inner tube and into the infuser device. The ejector tube slides with respect to the inner tube causing the distal end of the ejector tube to press against the infuser device, thereby ejecting the infuser device into the bladder. In one embodiment, a locking mechanism is deactivated before the step of sliding. Brief Description of the Drawings
FIG. 1 is a perspective view of a delivery device; FIG. 2 is a cross section of the delivery device of FIG. 1 taken along line A-A, FIG. 2A is an expanded view of the distal end of the tube portion.
FIG. 3 is a perspective view of an alternate embodiment of a delivery device with an infuser attached; FIG. 4 is a cross-section of a portion of the delivery device of FIG. 3 taken along line B-B; FIG. 5 is a perspective view of an obdurator; FIG. 6 is a perspective view of an introducer; and FIG. 6A is a perspective view of the obdurator installed within the introducer.
FIG. 7A 7F represent steps in utilizing the introducer and delivery device to place an infuser into a bladder. FIG. 8A 8C are front and perspective views of a locking mechanism.
Detailed Description of the Invention The present invention includes a unique delivery device and method suitable for delivering an infuser device into a body cavity such as the bladder. The invention can be used to introduce an infuser such as described in co- pending U.S. Patent application Serial No. 09/041,475, filed March 11 , 1998, titled "Intravesical Infuser", and also described in co pending U S. Provisional application Serial No. 60/130,750, filed April 23, 1999, titled "Pressure Responsive Valve For Use With An Intravesical Infuser", each of which is assigned to the assignee of the present invention and incorporated in its entirety herein. The delivery device can also be utilized to deliver an infuser into a body cavity, such as delivering an infuser into a bladder via the urethra, and then fill the infuser with a substance such as a drug. The delivery device can then be removed leaving the infuser in place in the body cavity.
With reference to FIG. 1 , the delivery device 10 has a handle portion 12 and tube portion 14 The tube portion can be rigid, flexible, semi flexible or a combination thereof. The rigidity and flexibility of the tube portion 14 can be varied according to, for example, whether the route to be traversed by the tube is straight or curved. Similarly, the length of the tube portion 14 can be varied according to the length of the route to be traversed by the delivery device. For example, the when the delivery device is used to deliver a device such as an infuser into a human bladder, the length of the tube portion 14 should exceed the length of the typical human urethra. Similarly, the overall diameter of the tube portion should correspond to the delivery route. For example, the diameter of the tube portion 14 should be such that it can safely be inserted into a human urethra when the urethra is to be the delivery routed into the bladder. The outer layer of the tube portion 14 visible in FIG. 1 is the ejector tube 24. A connector in the form of a distal luer fitting 16 is located at the distal end of the tube portion 14. An 0-rιng 18 is located at the beginning of a tapered portion 20 of the handle 12 A hollow generally cylindrical guide 22 for receiving a syringe barrel therein is located at the end of the handle 12 opposite the tube portion 14.
FIG. 2 is a cross-section of the delivery device of FIG. 1 taken along line A A. FIG. 2A is an expanded view of the distal portion B of the tube portion 14. The tube portion 14 includes an outer layer in the form of an ejector tube 24 which extends through the handle portion 12. The ejector tube passes through a front opening 34 in the handle 12 and extends through the handle 12, exiting through a rear opening 36 adjacent to the cylindrical guide 22. A trigger 26 is attached to the end of the ejector tube 24.
A hollow, inner tube 28 is located within the ejector tube 24. The inner tube 28 and the ejector tube 24 are moveable with respect to each other. The distal end of the inner tube 28 is coupled to and in fluid communication with the distal luer fitting 16. The distal luer fitting 16 can provide a releasable connection for a device, such as an infuser, that is to be delivered by the delivery device. At the proximal end, the inner tube 28 extends through an opening 38 in the wall of the ejector tube 24 within the handle 12. The proximal end of the inner tube 28 is coupled to and in fluid communication with a connector in the form of a second luer fitting 30. The second luer fitting 30 extends from the base 23 of the cylindrical guide 22 away from the inner tube 28. The second luer fitting 30 provides a connection for a device such as a syringe. The second luer fitting 30 can be formed as an integral part of the handle 12 or it can be formed as a separate part and attached to the handle 12 with an appropriate fastening mechanism such as epoxy or a mechanical fastener The luer fitting 30 forms an attachment point for the proximal end of the inner tube 28 and maintains the inner tube 28 in a fixed position with respect to the handle 12. The second luer fitting 30, inner tube 28 and distal luer fitting 16 form a delivery conduit. Fluid which is introduced through the luer fitting 30 can travel through inner tube 28 and exit through distal luer fitting 16. Luer fitting 30, inner tube 28 and luer fitting 16 form a lumen or pathway. Alternatively, more than one such lumen can be provided in the delivery device so that, for example, different substances can be separately transmitted through the delivery device. In addition, one or more optic fibers can be placed in the lumens to allow imaging. An adapter sleeve 32 is located in the distal end of the ejector tube 24 The adapter sleeve is fixed, such as with epoxy, to the ejector tube 24 and encircles the distal portion of the inner tube 28. The adapter sleeve 32 forms the distal end of the ejector tube 24
The ejector tube 24 is shdably retained within the front opening 34 and rear opening 36 of the handle 12 The ejector tube 24 can move shdably within those openings. The distance which the ejector tube 24 can slide is limited by the length of the opening 38 through which inner tube 28 passes. The edge of opening 38 coming into contact with inner tube 28 limits the travel of ejector tube 24.
The handle 12 includes the tapered portion 20 which extends from front opening 34 to a groove 42 which receives the 0 ring 18 (not shown in FIG. 2). An outer wall 44 of the handle 12 extends from the groove 42 to the end of the cylindrical guide 22. In one embodiment the handle 12 is formed in sections which are coupled together using male and female fittings 48 and an adhesive. If the delivery device is to be used to deliver a device that is not to be filed with a drug or other substance after it has been delivered into an organ or other location within a body, the delivery device can be simplified in that there would be no need for receiving a syringe barrel and being able to transmit the substance through the delivery device. All that would be required is the ability to retain the device until it is delivered or inserted and the ability to then release the device. Such would be the case, for example, when a monitoring device is being delivered. In a simplified version of the delivery device, only the inner tube 28 is provided. The inner tube 28 provides an end adapted to releasably connect to an infuser, such as the distal luer fitting 16 or alternative connection mechanisms such as a simple pressure fit or connection mechanisms known to those of skill in the art may be employed. The opposite end of the inner tube is then configured to receive a drug or other substance to be transmitted to the infuser via the conduit or lumen inside of the inner tube 28. For example, the opposite end may have a luer fitting configured to connect to a syringe.
An alternative embodiment of a delivery device is depicted in FIG. 3 and FIG. 4. Referring to FIG. 3, the delivery device 100 includes a handle portion 110 and a tube portion 1 12. The tube portion 1 12 can be rigid, flexible, semi-rigid or a combination thereof. The handle portion 110 includes a front handle 1 14 and a rear handle 1 16. A proximal luer connector 118 extends from the rear of the rear handle 1 16. A distal luer fitting 120 is located at the distal end of the tube portion 112. An infuser device 122 is shown coupled to the distal luer fitting 120.
Referring now to FIG. 4, a hollow inner tube 124 extends through a central, tubular passageway in the front handle 114. The inner tube 124 also extends through rear handle 116 and terminates at the luer connector 1 18. The inner tube 124 is fastened to the rear handle 116. The fastening can be accomplished through a friction fit or through the use of a fastener such as epoxy. The inner tube 124 can slide freely within the passageway in the front handle 114 through which it passes. The inner tube 124 also extends within the length of the ejector tube 126. The distal end of the inner tube 124 is connected to and in fluid communication with the distal luer fitting 120 (see FIG. 3). The inner tube 124 also slides freely within the ejector tube 126. The luer connector 1 18, inner tube 124 and distal luer fitting 120 form a delivery conduit. The ejector tube 126 extends partway into the front handle 114 and is firmly coupled to the front handle
114. The distal end of the ejector tube 126 may also include an adapter sleeve in the same manner as was described with respect to the delivery device shown in FIG. 2.
Movement of the rear handle 1 16 in the direction of arrow C and the front handle 1 14 in the direction of arrow D causes the inner tube to move in a direction opposite the movement of the ejector tube. This movement causes the distal luer fitting 120 to be withdrawn into the ejector tube. The withdrawal of the inner tube into the ejector tube causes the distal end of the ejector tube 129 (see FIG. 3) to come into contact with an end surface 131 of the infuser 122 thereby separating the infuser 122 from the distal luer fitting 120. In addition, prior to separation of the infuser 122 from the luer fitting 120, a liquid or semi-liquid can be introduced into the proximal luer connector 118, travel through the inner tube 124 and enter the infuser 122 through the distal lower fitting 120. Referring to FIG. 5, an obdurator 200 is shown. The obdurator 200 includes a rigid cylindrical shaft 210 having a dilator 212 at its distal end. The dilator 212 includes a cylindrical, tapered shaft 218 which extends distally from an opening 216 in the shaft 210 and terminates at a hemispherical tip 220. A base 214 is located at the proximal end of the obdurator 200, opposite to the dilator 212. FIG. 5A is a cross sectional view of the dilator 212. Referring to FIG. 5A, in one embodiment, the tapered shaft 218 is formed from soft, 20 50 shore A si cone and has a protrusion 213 which is configured to extend over the opening 216 A rigid portion 215 provide sufficient rigidity to the dilator 212 in order to be effective.
Referring to FIG. 6, an introducer 300 is depicted. The introducer 300 includes a hollow cylindrical tube 310 which extends from a hollow base 312. The hollow base 312 is configured to receive the base 214 of the obdurator 200 of FIG. 5 and the hollow tube 310 is configured to receive the shaft 210 of the obdurator. The markings 314 are placed at regular intervals along the exterior of the tube 310. The markings can be placed at intervals such as every 1 centimeter. The length of the tube 310 is such that when the obdurator 200 is fully inserted into the introducer 300, the dilator 212 of the obdurator 200 extends beyond the distal opening 316 of the introducer. Referring to FIG. 6A, the obdurator 200 is shown as installed within the introducer 300. In one embodiment, the tapered shaft 218 is large enough to extend over the opening 316 to provide a smooth transition for the comfort of the patient, and is pliable enough to compress and be retracted through the introducer 300.
Referring now to FIG. 7A F, a method for delivering a device such as an infuser into a body cavity utilizing the delivery device, obdurator and introducer will be described. Referring to FIG. 7A, the introducer 300 is shown with the obdurator 200 fully inserted into the introducer
200 such that the dilator 212 of the obdurator extends beyond the distal end 316 of the introducer. With the obdurator fully inserted into the introducer, that combination is then inserted along the urethra 412 and into the bladder 410 of a patient. The dilator 212 is preferably formed of a material and in a shape that minimizes possible trauma to the urethra as the dilator is moved along the urethra to the bladder (see FIG. 5A) The markings 314 (see FIG. 6) on the introducer can be used to assist in determining when the distal end 316 of the introducer has entered the bladder. After the dilator and the distal end 316 of the introducer have entered the bladder 410, the obdurator is removed from the introducer leaving the introducer in place as depicted in FIG. 7B. Alternatively, the delivery device 10 can serve as the obdurator thereby eliminating the need for a separate obdurator. In this embodiment it is advantageous to have the device being delivered be configured in a manner similar to the dilator 212. After the obdurator 200 has been withdrawn from the introducer 300 and the introducer remains in place, the introducer provides a pathway through the urethra 412 into the bladder 410
Referring to FIG 7C, the delivery device 10 is shown having an infuser 122 coupled to the distal luer fitting 16. Alternatively, any other device to be delivered would be in the position of the infuser 122. The barrel 412 of a syringe 400 is shown inserted into the cylindrical guide 22. A luer connector (not shown) at the end of the barrel 412 of the syringe 400 opposite to the plunger 414 has been connected to the second luer fitting 30 located within the cylindrical guide 22. Depressing the plunger 414 will cause fluid within the syringe barrel 412 to flow into the second luer fitting 30 through the inner tube 28 and out through the distal luer fitting 16 and into the infuser 122. However, prior to transferring the liquid within the syringe into the infuser, the infuser must be inserted into the bladder of the patient Referring to FIG. 7D, the tube portion 14 of the delivery device 10 is shown fully inserted into the introducer 300. The end of the distal luer connector reaches approximately the distal end of the introducer when the tube portion of the delivery device is fully inserted into the introducer. The infuser extends approximately completely beyond the distal end of the introducer within the bladder. Both the tube portion 14 and the infuser 122 have diameters such that they fit easily within and easily slide through tube 310. The tapered portion 20 of the delivery device 10 also fits within the hollow base 312 of the introducer when the delivery device is fully inserted into the introducer.
Referring to FIG. 7E, after the delivery device has been fully inserted into the introducer, the plunger 414 of the syringe is depressed, forcing the fluid contained within the syringe through the delivery device and into the infuser 122. After a predetermined amount of the fluid within the syringe 400 has been transferred into the infuser 122, the trigger 26 is moved forward (towards the infuser) which causes the distal end 37 of the ejector tube 24 to come into contact with the infuser 122 and force or eject the infuser from the distal luer fitting 120. The trigger 26 is pushed forward a distance sufficient to cause the distal end of the ejector tube to travel to approximately the end of the distal luer fitting 120, thereby releasing or disconnecting the infuser from the delivery device. Alternatively, other apparatus and/or techniques can be used to release the infuser. For example, the infuser can release itself from the delivery device when it has been filled with the drug. Referring to FIG. 7F, the infuser is shown disconnected from the delivery device and is free floating within the bladder. The delivery device and the introducer are then withdrawn through the urethra.
Alternatively, the delivery device and infuser (or other device to be delivered) can be inserted directly without the use of the introducer or obdurator.
In one embodiment, a lock mechanism is used to prevent the unintentional ejection of the infuser from the distal end of the luer fitting 120. Referring to FIG. 8A, 8B and 8C, one such locking mechanism 440 is shown in front view, in perspective view and installed on a delivery device, respectively. The locking mechanism 440 can be placed within the gap between the trigger 26 and the guide 22 such that the proximal end of the ejector tube 24 is between the extending members 442 as shown in FIG. 8C. The height, h, of the locking mechanism 440 prevents the movement of the ejector tube 24 toward the guide 22 and, thus, prevents the ejection of the infuser. The locking mechanism 440 can be in place until the infuser has been filled with drug. It can then be removed to allow the ejection of the infuser.
As was noted previously, an infuser with which the present invention finds particular usefulness is described in co-pending U.S. Patent application Serial No. 09/041 ,475, filed March 1 1 , 1998, titled Intravesical Infuser, and assigned to the assignee of the present invention. However, as will be appreciated by those of skill in the art, the delivery device can also be utilized to deliver other suitable objects into body cavities and to introduce liquid or semi- liquid materials into body cavities.
Although the invention has been described in terms of certain embodiments, other embodiments which will be apparent to those already skilled in the art, in view of the disclosure herein are also within the scope of this invention. Accordingly, the scope of the invention is intended to be defined only by reference to the appended claims

Claims

WHAT IS CLAIMED IS:
1. A delivery device suitable for delivering an infuser into a body cavity, the delivery device comprising: a handle; an ejector tube having a distal end, the ejector tube extending from the handle; and a hollow inner tube disposed within the ejector tube in a sliding relationship therewith, the hollow inner tube adapted to provide a passageway for a substance from the handle to a distal end of the hollow inner tube and said hollow inner tube having a fitting at the distal end of the hollow inner tube, the fitting adapted to couple to an infuser device, wherein the ejector tube is configured to slide distally relative to the inner tube and press against the infuser device causing ejection of the infuser device from the distal end of the hollow inner tube.
2. The delivery device of Claim 1 further comprising a locking mechanism configured to prevent the ejector tube from sliding with respect to the inner tube.
3. The delivery device of Claim 1 wherein the ejector tube is configured to be passed through the urethra of a mammalian.
4 The delivery device of Claim 1 wherein the hollow inner tube comprises two or more lumens.
5. The delivery device of Claim 1 further comprising a fiber optic element disposed within said hollow inner tube.
The delivery device of claim 1 further comprising a guide in the handle, configured to receive a syringe barrel.
7. A method of drug delivery comprising the steps of: inserting an introducer and obturator through the urethra of a mammal, withdrawing the obturator; inserting a delivery device through the introducer, the delivery device comprising a handle, an ejector tube, and a hollow inner tube shdably disposed within the ejector tube and coupled to an infuser device at the distal end thereof; passing a substance through the hollow inner tube from the handle to a distal end of the hollow inner tube and into the infuser device; and sliding the ejector tube distally with respect to the inner tube causing the distal end of the ejector tube to press against the infuser device, thereby ejecting the infuser device into the bladder.
8. The method of Claim 7 further comprising deactivating a locking mechanism before the step of sliding.
9. The method of claim 7 further comprising dispensing the substance from the infuser into the bladder.
10. A deliver apparatus suitable for delivering a device into a body cavity, the apparatus comprising: a handle; an ejector tube attached to said handle and having a proximal end and a distal end opposite said handle; and a inner tuber disposed within said ejector tube and capable of sliding with respect to said ejector tube such that a distal end of said inner tube can slide beyond the distal end of said ejector tube in a first direction and can slide in a second direction such that said inner tube does not extend beyond the distal end of said ejector tube.
1 1. The delivery apparatus of Claim 10 further comprising a lumen within said inner tube.
12. The apparatus of Claim 10 further comprising a coupling adjacent the distal end of said inner tube adapted to releaseably attach to a device to be inserted into a body cavity.
13. The apparatus of Claim 10 further comprising a luer fitting at a proximal end of said inner tube.
14 A deliver apparatus suitable for delivering an infuser into a bladder of a mammal, the apparatus comprising: a tube having a first end adapted to releasably connect to an infuser and having a second end, the tube further comprising a lumen extending from the first end to the second end to permit the transfer of a substance from the second end of the tube, through the lumen, out the first end and into the infuser connected to the first end, the tube having a length sufficient to extend through the urethra of the mammal, and the tube having an outer diameter such that said tube can be inserted into the urethra.
15. The apparatus of Claim 14 further comprising a luer connector at said first end of said tube. 16 The apparatus of Claim 14 further comprising an ejector extending to said first end of said tube and moveable with respect to said tube, wherein sliding said elector beyond said first end of said tube causes an infuser coupled to said first end to be released from said first end. 17 A method of introducing an infuser into the bladder of a mammal, the method comprising attaching an infuser to a first end of a delivery device having a hollow tube; inserting the infuser and the delivery device through the urethra such that the infuser enters the bladder and remains attached to the delivery device; transmitting a substance through the delivery device and into the infuser; and releasing the infuser within the bladder
PCT/US2000/029701 1999-10-28 2000-10-26 Method and apparatus for placement and activation of a medical device within a body cavity WO2001030420A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU17532/01A AU1753201A (en) 1999-10-28 2000-10-26 Method and apparatus for placement and activation of a medical device within a body cavity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42958999A 1999-10-28 1999-10-28
US09/429,589 1999-10-28

Publications (1)

Publication Number Publication Date
WO2001030420A1 true WO2001030420A1 (en) 2001-05-03

Family

ID=23703886

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/029701 WO2001030420A1 (en) 1999-10-28 2000-10-26 Method and apparatus for placement and activation of a medical device within a body cavity

Country Status (2)

Country Link
AU (1) AU1753201A (en)
WO (1) WO2001030420A1 (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925446A (en) 1988-07-06 1990-05-15 Transpharm Group Inc. Removable inflatable intragastrointestinal device for delivering beneficial agents
US5062829A (en) 1989-03-17 1991-11-05 Carter Holt Harvey Plastic Products Group Limited Relates to devices for administering a substance such as a drug or chemical or the like
US5219334A (en) 1989-05-24 1993-06-15 Tsukada Medical Research Co., Ltd. Infuser with balloon for continuously infusing liquid drug
US5301688A (en) 1992-08-07 1994-04-12 Physion S.R.L. Method for localization and therapy of occult bladder cancer
WO1996037167A1 (en) * 1995-05-25 1996-11-28 Raychem Corporation Stent assembly
US5733267A (en) * 1995-04-05 1998-03-31 Scimed Life Systems, Inc. Pull back stent delivery system
WO1999024106A1 (en) 1997-11-06 1999-05-20 Situs Corporation Intravesical infuser

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925446A (en) 1988-07-06 1990-05-15 Transpharm Group Inc. Removable inflatable intragastrointestinal device for delivering beneficial agents
US5062829A (en) 1989-03-17 1991-11-05 Carter Holt Harvey Plastic Products Group Limited Relates to devices for administering a substance such as a drug or chemical or the like
US5219334A (en) 1989-05-24 1993-06-15 Tsukada Medical Research Co., Ltd. Infuser with balloon for continuously infusing liquid drug
US5301688A (en) 1992-08-07 1994-04-12 Physion S.R.L. Method for localization and therapy of occult bladder cancer
US5733267A (en) * 1995-04-05 1998-03-31 Scimed Life Systems, Inc. Pull back stent delivery system
WO1996037167A1 (en) * 1995-05-25 1996-11-28 Raychem Corporation Stent assembly
WO1999024106A1 (en) 1997-11-06 1999-05-20 Situs Corporation Intravesical infuser

Also Published As

Publication number Publication date
AU1753201A (en) 2001-05-08

Similar Documents

Publication Publication Date Title
US6139535A (en) Method and apparatus for placement and activation of a medical device within a body cavity
JP2589967B2 (en) Catheter with atraumatic drug delivery tip
US4973301A (en) Catheter and method of using same
US6171298B1 (en) Intravesical infuser
US6183461B1 (en) Method for delivering a medication
EP0547463B1 (en) Catheter introducer assembly
US5527292A (en) Intravascular device for coronary heart treatment
AU742061B2 (en) Device for local administration of solid and semisolid formulations, sustained-release formulations for parenteral administration and method of preparation
US4559046A (en) Apparatus for intravenous therapy and hyperalimentation
US7452354B2 (en) Implantable pump connector for catheter attachment
US6402735B1 (en) Medical tube collar
US6517520B2 (en) Peripherally inserted catheter with flushable guide-tube
EP0593741B2 (en) Improved biliary catheter
EP1025802A1 (en) Percutaneous device anchoring system
EP0208787B1 (en) Medical guiding micro-tube
US20230096377A1 (en) Couplers and Assemblies Thereof for Rapidly Insertable Central Catheters
EP0098688A1 (en) Intratubular medication dispenser
WO2001030420A1 (en) Method and apparatus for placement and activation of a medical device within a body cavity
EP2346559A1 (en) Medical device
CN115397498A (en) Intermittent urinary catheter component
US6139539A (en) Microbore catheter with velocity reducing chamber
CN215231398U (en) Conveying sleeve
JPS63117768A (en) Removable funnel catheter
MXPA00004326A (en) Intravesical infuser
IE20040803U1 (en) Drug delivery device

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP